GlassScriptPhysician profile
Christopher R Moll
NPI 1851917397
$1,766.76
in general payments reported to CMS, 2019-2025
27 companies · $18.86 in 2025
The $18.86 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $337 · 2024: $1,411 · 2025: $18.86.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,767.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,766.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $429.89 | 2023-2024 | |
| Gilead Sciences, INC. | $334.51 | 2023-2024 | |
| Novo Nordisk INC | $130.80 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Eisai INC. | $96.67 | 2024 | |
| Corium, LLC | $92.89 | 2023-2024 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $80.30 | 2023-2024 | Trintellix |
| Shield Therapeutics INC | $74.98 | 2024 | |
| Pfizer INC. | $71.19 | 2024 | |
| Alexion Pharmaceuticals, INC. | $49.57 | 2024 | Ultomiris |
| Inspire Medical Systems, INC. | $45.10 | 2024 | Inspire |
| Hologic Sales and Service, LLC | $37.65 | 2023-2024 | Aptima |
| Seqirus USA INC | $33.28 | 2024 | Flucelvax |
| Exeltis, USA INC. | $31.82 | 2024 | Slynd |
| Otsuka America Pharmaceutical, INC. | $27.37 | 2024 | Abilify Mycite |
| Genzyme Corporation | $24.69 | 2024 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $22.19 | 2023 | Opzelura |
| Alkermes, INC. | $21.60 | 2024 | Vivitrol |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.12 | 2023 | Xifaxan |
| Sanofi-Aventis U.S. LLC | $16.77 | 2024 | |
| Linus Health, INC. | $16.58 | 2024 | Core Cognitive Evaluation |
| Idorsia Pharmaceuticals US INC | $16.45 | 2024 | Quviviq |
| Qiagen, LLC | $16.18 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $15.94 | 2024 | Airsupra |
| Lundbeck LLC | $15.92 | 2024 | Rexulti |
| Supernus Pharmaceuticals, INC. | $15.62 | 2023 | Qelbree |
| Noven Therapeutics, LLC | $14.48 | 2024 | Xelstrym |
| Novartis Pharmaceuticals Corporation | $14.20 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Moll listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.